NTAGI may soon review efficacy data of India's first intranasal Covid vaccine

The date of the meeting is yet to be fixed. India's drug controller had in January this year given permission to Bharat Biotech to conduct standalone phase III trials on its Covid-19 intranasal vaccine. The company also received approval to evaluate the intranasal vaccine, BBV 154, as a booster dose on those who have already received both doses of Covaxin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FTDgCWB
via IFTTT